Provention bio announces update to board of directors

Red bank, n.j. , june 3, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced dr. jeffrey bluestone's decision to step down as a director on the company's board of directors to focus on his other commitments, including his role as president and chief executive officer of sonoma biotherapeutics.
PRVB Ratings Summary
PRVB Quant Ranking